Cargando…

Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry

This study aimed to investigate drug retention rates for various TNF inhibitors (TNFis) commonly prescribed to Korean patients with ankylosing spondylitis (AS) in the Korean College of Rheumatology Biologics registry (KOBIO; December 2012–June 2016). Discontinuation was defined as switching or stopp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyoun-Ah, Lee, Sun-Kyung, Oh, Sohee, Park, Eun Hye, Park, Yong-Beom, Shin, Kichul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239349/
https://www.ncbi.nlm.nih.gov/pubmed/34211991
http://dx.doi.org/10.3389/fmed.2021.689609
_version_ 1783715059611992064
author Kim, Hyoun-Ah
Lee, Sun-Kyung
Oh, Sohee
Park, Eun Hye
Park, Yong-Beom
Shin, Kichul
author_facet Kim, Hyoun-Ah
Lee, Sun-Kyung
Oh, Sohee
Park, Eun Hye
Park, Yong-Beom
Shin, Kichul
author_sort Kim, Hyoun-Ah
collection PubMed
description This study aimed to investigate drug retention rates for various TNF inhibitors (TNFis) commonly prescribed to Korean patients with ankylosing spondylitis (AS) in the Korean College of Rheumatology Biologics registry (KOBIO; December 2012–June 2016). Discontinuation was defined as switching or stopping the biologic agent. Kaplan–Meier curves and Cox's proportional hazard models were used for further analysis. The reasons for discontinuation of TNFis were also assessed. Univariate and multivariate analyses were used to identify possible predictors of discontinuation. Data from 1,005 patients with AS were analyzed with a median follow-up period of 14 months. Seventy-six percent of patients were first-line biologic users. Discontinuation of TNFis occurred in 24.2% (switching in 9.6%) of patients during follow-up. An estimate of the drug failure showed that the adjusted hazard ratio (HR) for golimumab compared to etanercept was 0.441 (95% confidence interval: 0.277–0.703, p < 0.001). Reasons for discontinuation included lack of efficacy (32.6%), adverse events (23.6%), clinical improvement (11.2%), and others (32.6%). Predictors of discontinuation using a multivariate analysis were a shorter disease duration (HR: 0.973, p = 0.044) and being negative for HLA-B27 (HR: 1.623, p = 0.0093). In conclusion, few Korean patients with AS switched to other TNFis during their treatment. The drug retention rate for golimumab was higher than for other agents.
format Online
Article
Text
id pubmed-8239349
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82393492021-06-30 Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry Kim, Hyoun-Ah Lee, Sun-Kyung Oh, Sohee Park, Eun Hye Park, Yong-Beom Shin, Kichul Front Med (Lausanne) Medicine This study aimed to investigate drug retention rates for various TNF inhibitors (TNFis) commonly prescribed to Korean patients with ankylosing spondylitis (AS) in the Korean College of Rheumatology Biologics registry (KOBIO; December 2012–June 2016). Discontinuation was defined as switching or stopping the biologic agent. Kaplan–Meier curves and Cox's proportional hazard models were used for further analysis. The reasons for discontinuation of TNFis were also assessed. Univariate and multivariate analyses were used to identify possible predictors of discontinuation. Data from 1,005 patients with AS were analyzed with a median follow-up period of 14 months. Seventy-six percent of patients were first-line biologic users. Discontinuation of TNFis occurred in 24.2% (switching in 9.6%) of patients during follow-up. An estimate of the drug failure showed that the adjusted hazard ratio (HR) for golimumab compared to etanercept was 0.441 (95% confidence interval: 0.277–0.703, p < 0.001). Reasons for discontinuation included lack of efficacy (32.6%), adverse events (23.6%), clinical improvement (11.2%), and others (32.6%). Predictors of discontinuation using a multivariate analysis were a shorter disease duration (HR: 0.973, p = 0.044) and being negative for HLA-B27 (HR: 1.623, p = 0.0093). In conclusion, few Korean patients with AS switched to other TNFis during their treatment. The drug retention rate for golimumab was higher than for other agents. Frontiers Media S.A. 2021-06-15 /pmc/articles/PMC8239349/ /pubmed/34211991 http://dx.doi.org/10.3389/fmed.2021.689609 Text en Copyright © 2021 Kim, Lee, Oh, Park, Park and Shin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Kim, Hyoun-Ah
Lee, Sun-Kyung
Oh, Sohee
Park, Eun Hye
Park, Yong-Beom
Shin, Kichul
Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry
title Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry
title_full Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry
title_fullStr Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry
title_full_unstemmed Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry
title_short Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry
title_sort comparison of retention rates between tumor necrosis factor-α inhibitors in patients with ankylosing spondylitis: data from the korean college of rheumatology biologics registry
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239349/
https://www.ncbi.nlm.nih.gov/pubmed/34211991
http://dx.doi.org/10.3389/fmed.2021.689609
work_keys_str_mv AT kimhyounah comparisonofretentionratesbetweentumornecrosisfactorainhibitorsinpatientswithankylosingspondylitisdatafromthekoreancollegeofrheumatologybiologicsregistry
AT leesunkyung comparisonofretentionratesbetweentumornecrosisfactorainhibitorsinpatientswithankylosingspondylitisdatafromthekoreancollegeofrheumatologybiologicsregistry
AT ohsohee comparisonofretentionratesbetweentumornecrosisfactorainhibitorsinpatientswithankylosingspondylitisdatafromthekoreancollegeofrheumatologybiologicsregistry
AT parkeunhye comparisonofretentionratesbetweentumornecrosisfactorainhibitorsinpatientswithankylosingspondylitisdatafromthekoreancollegeofrheumatologybiologicsregistry
AT parkyongbeom comparisonofretentionratesbetweentumornecrosisfactorainhibitorsinpatientswithankylosingspondylitisdatafromthekoreancollegeofrheumatologybiologicsregistry
AT shinkichul comparisonofretentionratesbetweentumornecrosisfactorainhibitorsinpatientswithankylosingspondylitisdatafromthekoreancollegeofrheumatologybiologicsregistry